Silverback Therapeutics

Silverback Therapeutics

Silverback Therapeutics was established as a biotech-focused entity, with its name and website (silverbacktx.com) suggesting a concentration on therapeutic development. The firm's office network — New York, Zurich, Boston, Seattle, and New Canaan — indicates a distributed operational model, common among asset managers that source deals and talent across multiple innovation hubs. No founding year, founder, or wealth origin is publicly disclosed. The firm's strategy appears centered on biotechnology and pharmaceutical investments, likely encompassing both public equities and private placements. The therapeutic focus may include immuno-oncology, given the industry trend and the 'silverback' nomenclature associated with dominant biological mechanisms. Geographic coverage spans North America and Europe, with a presence in the US Northeast, Pacific Northwest, and Continental Europe. Without disclosed portfolio companies or deals, the exact asset-class mix remains unclear; potential areas include venture-stage biotech, public biotech equities, or structured partnerships. Team size, total deployment, and any adjacent philanthropic vehicles are not publicly reported. The five-office footprint implies a team capable of cross-border due diligence, but no recent operational events — such as fund closes or major hires — have been confirmed in the last 24 months. No additional vehicles like foundations or operating companies have been identified. The structural differentiator for Silverback Therapeutics lies in its multi-city, cross-continent office setup, which is unusual for a biotech investment firm. This may enable it to capture proprietary deal flow from research hubs in both the US and Europe. However, the absence of public filings or media coverage suggests it operates as a private investment vehicle, possibly a family office or boutique asset manager, rather than a registered fund.